News for ALTEOGEN Inc. (196170.KQ)

AstraZeneca: Revenue and EPS summary Q1 2025 % Change $m Actual CER1 - Product Sales 12,875 6 9 - Alliance Revenue 639

AstraZeneca acquires EsoBiotec for $1 billion to enhance cancer treatment capabilities, with potential for revolutionary cell therapy.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial.

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a subcutaneous version of ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate (ADC) that has been jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA) for Tergase® (recombinant hyaluronidase).

Altos Biologics Files Approval of Aflibercept Biosimilar

Park Soon-jae, founder and CEO of Alteogen, joins the three-comma club after his company announced a licensing deal with the U.S. drug giant.

Here’s how Placental Growth Factors Help in Prediction, Diagnosis, and Treatment of Pre-eclampsia Conditions? FMI Predicts the Market to Surpass US$ 64.6...

Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock.

/PRNewswire/ -- The

Coya Therapeutics, Inc. , a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells , today announced its financial... | May 10, 2023